Findings

What do systematic reviews say?

106 questions · 115 findings · 12 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 27 · 23.5%GRADE not reported 13 · 11.3%Very low 45 · 39.1%Low 17 · 14.8%Moderate 8 · 7%High 5 · 4.3%

Aspirin 1000 mg vs placebo

Specific adverse events · adults with episodic tension‐type headache

1 finding from 1 review

Aspirin for acute treatment of episodic tension‐type headache in adults 2017 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 767 participants
Very low

Aspirin 1000 mg vs placebo

Serious adverse events · adults with episodic tension‐type headache

1 finding from 1 review

Aspirin for acute treatment of episodic tension‐type headache in adults 2017 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 767 participants
Very low

Low‐dose aspirin vs placebo or no treatment

Live birth · women with subfertility

Low‐dose aspirin showed no clear difference in live birth compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Aspirin for in vitro fertilisation 2016 · Cochrane Headline outcomes only
RR 0.91 [0.72, 1.15]
3 studies · 1053 participants
Moderate

Low‐dose aspirin vs placebo or no treatment

Clinical pregnancy · women with subfertility

Low‐dose aspirin showed no clear difference in clinical pregnancy compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Aspirin for in vitro fertilisation 2016 · Cochrane Headline outcomes only
RR 1.03 [0.91, 1.17]
10 studies · 2142 participants
Moderate

Low‐dose aspirin vs placebo or no treatment

Multiple pregnancy · women with subfertility

Low‐dose aspirin showed no clear difference in multiple pregnancy (on ultrasound) compared with placebo or no treatment (low certainty).

1 finding from 1 review

Aspirin for in vitro fertilisation 2016 · Cochrane Headline outcomes only
RR 0.67 [0.37, 1.25]
2 studies · 656 participants
Low

Low‐dose aspirin vs placebo or no treatment

Miscarriage · women with subfertility

Low‐dose aspirin showed no clear difference in miscarriage rate per woman compared with placebo or no treatment (low certainty).

1 finding from 1 review

Aspirin for in vitro fertilisation 2016 · Cochrane Headline outcomes only
RR 1.1 [0.68, 1.77]
5 studies · 1497 participants
Low

Low‐dose aspirin vs placebo or no treatment

Ectopic pregnancy · women with subfertility

It is very uncertain whether low‐dose aspirin changes ectopic pregnancy compared with placebo or no treatment (very low certainty).

1 finding from 1 review

Aspirin for in vitro fertilisation 2016 · Cochrane Headline outcomes only
RR 1.86 [0.75, 4.63]
3 studies · 1135 participants
Very low

Low‐dose aspirin vs placebo or no treatment

Vaginal bleeding · women with subfertility

It is very uncertain whether low‐dose aspirin changes vaginal bleeding compared with placebo or no treatment (very low certainty).

1 finding from 1 review

Aspirin for in vitro fertilisation 2016 · Cochrane Headline outcomes only
RR 1.01 [0.14, 7.13]
1 study · 487 participants
Very low

Low‐dose aspirin vs placebo or no treatment

Other adverse events · women with subfertility

The review found no eligible studies for this question.

1 finding from 1 review

Aspirin for in vitro fertilisation 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Interventions (ibuprofen, tolfenamic acid, aspirin, tranexamic acid) vs placebo or active comparators (paracetamol, tranexamic acid)

Aspirin vs paracetamol

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Aspirin vs vitamin K antagonist (VKA)

All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether aspirin (ASA) changes all‐cause mortality compared with vitamin K antagonist (VKA) (very low certainty).

2 findings from 1 review

Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes only
RR 3 [0.12, 73.24]
1 study · 440 participants
Very low
Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes only
RR 0.5 [0.05, 5.47]
1 study · 440 participants
Very low

Aspirin vs vitamin K antagonist (VKA)

Minor bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents

The review found no eligible studies for this question.

1 finding from 1 review

Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Aspirin vs low molecular weight heparin

All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether aspirin (ASA) changes all‐cause mortality compared with low molecular weight heparin (LMWH) (very low certainty).

2 findings from 1 review

Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes only
RR 1 [0.06, 15.81]
2 studies · 781 participants
Very low
Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes only
RR 1 [0.06, 15.89]
1 study · 440 participants
Very low

Aspirin vs low molecular weight heparin

Symptomatic DVT · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether aspirin (ASA) changes symptomatic deep vein thrombosis compared with low molecular weight heparin (LMWH) (very low certainty).

2 findings from 1 review

Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes only
RR 1.23 [0.49, 3.08]
2 studies · 781 participants
Very low
Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes only
RR 1.2 [0.53, 2.72]
1 study · 440 participants
Very low

Aspirin vs low molecular weight heparin

Pulmonary embolism · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether aspirin (ASA) changes pulmonary embolism compared with low molecular weight heparin (LMWH) (very low certainty).

2 findings from 1 review

Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes only
RR 7.71 [0.97, 61.44]
2 studies · 781 participants
Very low
Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes only
RR 9 [0.49, 166.17]
1 study · 440 participants
Very low

Aspirin vs low molecular weight heparin

Major bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether aspirin (ASA) changes major bleeding compared with low molecular weight heparin (LMWH) (very low certainty).

2 findings from 1 review

Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes only
RR 6.97 [0.36, 134.11]
2 studies · 781 participants
Very low
Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Aspirin vs low molecular weight heparin

Minor bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether aspirin (ASA) changes minor bleeding compared with low molecular weight heparin (LMWH) (very low certainty).

1 finding from 1 review

Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes only
RR 1.42 [0.35, 5.78]
2 studies · 781 participants
Very low

Aspirin vs vitamin K antagonist (VKA)

Symptomatic DVT · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether aspirin (ASA) changes symptomatic deep vein thrombosis compared with vitamin K antagonist (VKA) (very low certainty).

2 findings from 1 review

Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes only
RR 0.57 [0.24, 1.33]
1 study · 440 participants
Very low
Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes only
RR 0.71 [0.35, 1.44]
1 study · 440 participants
Very low

Aspirin vs low molecular weight heparin

Minor bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents

The review found no eligible studies for this question.

1 finding from 1 review

Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Aspirin vs vitamin K antagonist (VKA)

Pulmonary embolism · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether aspirin (ASA) changes pulmonary embolism compared with vitamin K antagonist (VKA) (very low certainty).

2 findings from 1 review

Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes only
RR 1 [0.25, 3.95]
1 study · 440 participants
Very low
Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes only
RR 1 [0.25, 3.95]
1 study · 440 participants
Very low